M

Mankind Pharma Ltd
NSE:MANKIND

Watchlist Manager
Mankind Pharma Ltd
NSE:MANKIND
Watchlist
Price: 2 365 INR -0.3%
Market Cap: 975.8B INR
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+22%
Revenue
Forecast
+8%
Operating Income
Forecast
+8%
Net Income
Forecast
+10%

Wall Street
Price Targets

MANKIND Price Targets Summary
Mankind Pharma Ltd

Wall Street analysts forecast MANKIND stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MANKIND is 2 842.3 INR with a low forecast of 2 171.5 INR and a high forecast of 3 465 INR.

MANKIND Lowest Forecast
Wall Street Target
2 171.5 INR
8% Downside
MANKIND Average Forecast
Wall Street Target
2 842.3 INR
20% Upside
MANKIND Highest Forecast
Wall Street Target
3 465 INR
47% Upside
Lowest
Price Target
2 171.5 INR
8% Downside
Average
Price Target
2 842.3 INR
20% Upside
Highest
Price Target
3 465 INR
47% Upside
Mankind Pharma Ltd Competitors:
Price Targets
MRK
Merck KGaA
40% Upside
VETO
Vetoquinol SA
15% Upside
MYX
Mayne Pharma Group Ltd
4% Upside
600276
Jiangsu Hengrui Pharmaceuticals Co Ltd
36% Upside
MRK
Merck KGaA
40% Upside
VETO
Vetoquinol SA
15% Upside
MYX
Mayne Pharma Group Ltd
4% Upside
600276
Jiangsu Hengrui Pharmaceuticals Co Ltd
36% Upside
D
DPHARMA
Duopharma Biotech Bhd
26% Upside

Revenue
Forecast

Revenue Estimate
Mankind Pharma Ltd

For the last 3 years the compound annual growth rate for Mankind Pharma Ltd's revenue is 18%. The projected CAGR for the next 3 years is 18%.

18%
Past Growth
18%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Mankind Pharma Ltd

For the last 3 years the compound annual growth rate for Mankind Pharma Ltd's operating income is 11%. The projected CAGR for the next 3 years is 21%.

11%
Past Growth
21%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Mankind Pharma Ltd

For the last 3 years the compound annual growth rate for Mankind Pharma Ltd's net income is 15%. The projected CAGR for the next 3 years is 17%.

15%
Past Growth
17%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
MANKIND intrinsic value, competitors valuation, and company profile.
DCF Valuation
MANKIND stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MANKIND stock valuation using valuation multiples.
Wall Street Estimates
MANKIND price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MANKIND stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is MANKIND's stock price target?
Price Target
2 842.3 INR

According to Wall Street analysts, the average 1-year price target for MANKIND is 2 842.3 INR with a low forecast of 2 171.5 INR and a high forecast of 3 465 INR.

What is Mankind Pharma Ltd's Revenue forecast?
Projected CAGR
18%

For the last 3 years the compound annual growth rate for Mankind Pharma Ltd's revenue is 18%. The projected CAGR for the next 3 years is 18%.

What is Mankind Pharma Ltd's Operating Income forecast?
Projected CAGR
21%

For the last 3 years the compound annual growth rate for Mankind Pharma Ltd's operating income is 11%. The projected CAGR for the next 3 years is 21%.

What is Mankind Pharma Ltd's Net Income forecast?
Projected CAGR
17%

For the last 3 years the compound annual growth rate for Mankind Pharma Ltd's net income is 15%. The projected CAGR for the next 3 years is 17%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 241,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.